Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hims and Hers Health Inc (HIMS) vs Infosys Limited (INFY) Price & Performance

Hims and Hers Health IncTrade
Infosys LimitedTrade

Price performance (Past 24H)

Key statistics

Hims and Hers Health Inc vs Infosys Limited — how do they compare? Hims and Hers Health Inc trades at $29.97 (market cap $7.12B), while Infosys Limited trades at $12.6 (market cap $50.55B). The key difference: Infosys Limited is far larger — about 7.1× Hims and Hers Health Inc's market cap, and Infosys Limited pays a 4.16% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.

HIMSINFY
Market Cap
$7.12B$50.55B
Sector
HealthTechnology
52-Week High
$62.76$20.22
52-Week Low
$14.52$10.49
Enterprise Value
$7.82B$48.30B
Dividend Yield
4.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hims and Hers Health Inc

HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.

The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.

Infosys Limited

INFY trades at $12.28, down 2.23% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported Q1 2027 revenue below expectations but maintained strong margins and AI growth, with a P/E of 15.56 and robust ROE of 32.12%. Recent news includes strategic AI collaborations and a CEO transition, while analyst sentiment remains cautious with a consensus price target of $11.05.

The outlook for INFY is balanced; solid profitability and AI adoption offer upside, but near-term revenue softness and elevated valuation pose risks. Investors should weigh strong cash flow and market position against competitive pressures and execution challenges in a volatile IT services market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS

About Infosys Limited

Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.

Read more on INFY